Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT06759077
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Potential Beneficial Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Sponsor: Al-Azhar University
Conditions
Kidney Diseases
Interventions
Dapagliflozin (DAPA)
Updated 1 time since 2025 Last updated: Jan 7, 2025 Started: Dec 28, 2024 Primary completion: Dec 28, 2024 Completion: Dec 28, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06759077, this PHASE3 trial focuses on Kidney Diseases and remains ongoing. Sponsored by Al-Azhar University, it has been updated 1 time since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Active Not Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Al-Azhar University
Data source: Al-Azhar University
For direct contact, visit the study record on ClinicalTrials.gov .